Suchergebnisse - "Ying, Jieer"

PubPharm (84)

1

Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer : Results From a Randomized, Open-Label Phase II Study

enthalten in: The oncologist | 2024

von Wei, Q. | Xu, X. | Li, J. | +12

2

Spatiotemporal Quantification of HER2-targeting Antibody-Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Wei, Q. | Yang, T. | Zhu, J. | +13

3

Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer : a phase Ⅱ study

enthalten in: EBioMedicine | 2024

von Yang, L. | Zhang, W. | Fan, N. | +24

4

XYA-2 : a marine-derived compound targeting apoptosis and multiple signaling pathways in pancreatic cancer

enthalten in: PeerJ | 2024

von Guan, X. | Li, Y. | Guan, X. | +2

5

The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

enthalten in: Journal of hematology & oncology | 2024

von Wei, Q. | Li, P. | Yang, T. | +14

6

The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

enthalten in: Journal of hematology & oncology | 2024

von Wei, Q. | Li, P. | Yang, T. | +14

7

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002) : a randomised, double-blind, phase 3 trial

enthalten in: The Lancet. Oncology | 2023

von Llovet, J. | Kudo, M. | Merle, P. | +123

ErratumIn: Lancet Oncol. 2024 Apr;25(4):e137. - PMID 38547896

8

Beyond ENO1, emerging roles and targeting strategies of other enolases in cancers

enthalten in: Molecular therapy oncolytics | 2023

von Ni, J. | Huang, Y. | Li, C. | +2

9

Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer : The ORIENT-16 Randomized Clinical Trial

enthalten in: JAMA | 2023

von Xu, J. | Jiang, H. | Pan, Y. | +66

CommentIn: JAMA. 2024 Apr 16;331(15):1333-1334. - PMID 38512227

10

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050) : a randomised, open-label, multicentre, phase 3 trial

enthalten in: Lancet (London, England) | 2023

von Qin, S. | Chen, M. | Cheng, A. | +122

CommentIn: Lancet. 2023 Nov 18;402(10415):1806-1807. - PMID 37883983

1
2
3
4
5
6
7
8
9
Nächster »
[9]